21:48 , Apr 2, 2019 |  BC Innovations  |  Distillery Therapeutics

Conbriza bazedoxifene for MS and other demyelinating diseases

DISEASE CATEGORY: Autoimmune disease; neurology INDICATION: Multiple sclerosis (MS); neurology Cell culture and mouse studies suggest Conbriza bazedoxifene could help treat MS and other demyelinating diseases. In oligodendrocyte precursor cells (OPCs) derived from a human...
08:00 , Feb 2, 2015 |  BC Week In Review  |  Clinical News

Duavive conjugated estrogens/bazedoxifene regulatory update

The European Commission approved Duavive conjugated estrogens/bazedoxifene from Pfizer to treat estrogen deficiency symptoms in postmenopausal women with a uterus for whom progestin-containing therapy is inappropriate. Pfizer markets the drug in the U.S. as Duavee...
08:00 , Nov 10, 2014 |  BC Week In Review  |  Clinical News

Duavive conjugated estrogens/bazedoxifene regulatory update

EMA's CHMP recommended approval of Duavive conjugated estrogens/bazedoxifene from Pfizer to treat estrogen deficiency in postmenopausal women for whom progestin-containing therapy is inappropriate. FDA approved the drug as Duavee last year to treat moderate to...
08:00 , Nov 18, 2013 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 11/15 cls Cellular Dynamics International Inc. (NASDAQ:ICEL) Leerink Dan Leonard Downgrade Market perform (from outperform) -5% $14.79 Leonard downgraded but maintained his $15 target...
07:00 , Oct 14, 2013 |  BC Week In Review  |  Clinical News

Duavee conjugated estrogens/bazedoxifene regulatory update

Pfizer and partner Ligand said FDA approved an NDA for 0.45 mg/20 mg Duavee conjugated estrogens/bazedoxifene (CE/BZA) to treat moderate to severe vasomotor symptoms (VMS) associated with menopause in non-hysterectomized women and to prevent postmenopausal...
07:00 , Jul 1, 2013 |  BioCentury  |  Finance

3Q Financial Markets Preview: Punctuated equilibrium

Buysiders are viewing 3Q13 as a relatively quiet quarter punctuated by some important clinical and commercial milestones for a few of biotech's bigger names, notably Celgene Corp. and Biogen Idec Inc. The under $200 million...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Clinical News

Bazedoxifene/conjugated estrogens regulatory update

Ligand and Pfizer said FDA accepted for review an NDA for bazedoxifene/conjugated estrogens (BZA/CE) to treat non-hysterectomized women with moderate to severe vasomotor symptoms (VMS) and vulvar and vaginal atrophy (VVA) associated with menopause, as...
07:00 , Jul 23, 2012 |  BC Week In Review  |  Clinical News

Bazedoxifene/conjugated estrogens regulatory update

Pfizer said EMA accepted for review an MAA for bazedoxifene/conjugated estrogens (BZA/CE) to treat symptoms associated with menopause and osteoporosis. The company said it expects a decision in 2013. Pfizer has rights to the tissue...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Clinical News

Bazedoxifene/conjugated estrogens: Phase III data

The double-blind, international Phase III SMART-5 trial in 1,843 non-hysterectomized, postmenopausal women showed that once-daily low- and high-dose oral bazedoxifene/conjugated estrogens (BZA/CE) (20 mg/0.45 mg and 20 mg/0.625 mg) led to 1-year rates of endometrial...
07:00 , Aug 31, 2009 |  BioCentury  |  Strategy

Ligand pipeline

Ligand pipeline Partner Ph I Ph II Ph III Approved/Marketed Abbott Laboratories (NYSE:ABT) • LGD-2941 - hypogonadism Bristol-Myers Squibb Co. (NYSE:BMY) • PS540446 - rheumatoid arthritis (RA), psoriasis, atherosclerosis (A) Celgene Corp. (NASDAQ:CELG) • PS873266...